Ovid Therapeutics (NASDAQ:OVID – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They currently have a $3.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 165.49% from the stock’s current price.
Other equities analysts have also recently issued research reports about the stock. B. Riley lowered their price objective on shares of Ovid Therapeutics from $9.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, June 18th. Citigroup decreased their price target on shares of Ovid Therapeutics from $3.50 to $1.20 and set a “neutral” rating for the company in a research report on Tuesday, June 18th. Oppenheimer cut shares of Ovid Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 18th. Finally, BTIG Research decreased their price target on shares of Ovid Therapeutics from $11.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, June 18th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Ovid Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $4.70.
View Our Latest Research Report on Ovid Therapeutics
Ovid Therapeutics Stock Performance
Institutional Investors Weigh In On Ovid Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD grew its position in Ovid Therapeutics by 22.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 17,396 shares of the company’s stock worth $54,000 after purchasing an additional 3,145 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Ovid Therapeutics by 66.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 13,579 shares of the company’s stock worth $41,000 after purchasing an additional 5,401 shares during the last quarter. Empowered Funds LLC grew its position in Ovid Therapeutics by 8.1% during the 1st quarter. Empowered Funds LLC now owns 128,070 shares of the company’s stock worth $391,000 after purchasing an additional 9,625 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Ovid Therapeutics by 74.7% during the first quarter. BNP Paribas Financial Markets now owns 32,162 shares of the company’s stock worth $98,000 after buying an additional 13,756 shares in the last quarter. Finally, DCF Advisers LLC boosted its holdings in Ovid Therapeutics by 111.6% during the second quarter. DCF Advisers LLC now owns 41,750 shares of the company’s stock worth $32,000 after buying an additional 22,020 shares in the last quarter. 72.24% of the stock is currently owned by institutional investors and hedge funds.
Ovid Therapeutics Company Profile
Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.
Read More
- Five stocks we like better than Ovid Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
- 3 Warren Buffett Stocks to Buy Now
- Microvast vs. FREYR: Which Battery Stock Holds the Power?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Retail Earnings: Value, Caution, and Luxury in a Shifting Market
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.